Furo[3,2-c]pyrazole derivatives of formula (I) as defined in the description, and pharmaceutically acceptable salts thereof, wherein A is an aryl or heteroaryl ring, --NHZR.sub.5 is at the ortho position to the CONH linker; --R.sub.1 and R.sub.2 are the same or different and, independently from each other, represent a hydrogen atom, or an organic residue; R.sub.3 is a hydrogen or halogen atom or an organic group; R.sub.4 is a hydrogen or halogen atom or an organic group; Z is direct bond, >C.dbd.O, or --C(.dbd.O)NH--; --R.sub.5 is hydrogen or an optionally substituted organic group or isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts thereof. A process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, in particular Aurora kinases activity or IGF-1R activity, like cancer. ##STR00001##